Showing 141 - 160 results of 41,441 for search '(((( ((b large) OR (a large)) decrease ) OR ( i care increased ))) OR ( c large decrease ))', query time: 2.56s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145

    Discovery of an <i>In Vivo</i> Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones by Alice C. Harnden (15197268)

    Published 2023
    “…Careful optimization of these properties, as guided by pharmacokinetic studies, led to the discovery of <b>CCT374705</b>, a potent inhibitor of BCL6 with a good <i>in vivo</i> profile. …”
  6. 146

    Discovery of an <i>In Vivo</i> Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones by Alice C. Harnden (15197268)

    Published 2023
    “…Careful optimization of these properties, as guided by pharmacokinetic studies, led to the discovery of <b>CCT374705</b>, a potent inhibitor of BCL6 with a good <i>in vivo</i> profile. …”
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151

    Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  12. 152

    Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  13. 153

    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  14. 154

    Table1_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.DOCX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  15. 155

    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  16. 156

    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  17. 157
  18. 158

    Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  19. 159

    Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  20. 160